Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PEPD | P12955 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.42 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895536 | 0.84 | ALDH1A1 (0.59) | ALDH1A1GLAHSD17B10SRCGAA | |
| SCHEMBL4027043 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GLAHSD17B10PEPDNPC1 | |
| SCHEMBL3905819 | 0.82 | ALDH1A1 (0.61) | ALDH1A1GLAHSD17B10SRCGAA | |
| SCHEMBL17144199 | 0.81 | SRC (0.55) | ALDH1A1NPC1SRCMAPTMEN1 | |
| SCHEMBL2340576 | 0.80 | MEN1 (0.61) | ALDH1A1HSD17B10SRCMAPTMEN1 | |
| SCHEMBL29102156 | 0.77 | SRC (0.54) | SRCMEN1LMNAKMT2ACA1 | |
| SCHEMBL907356 | 0.76 | TGM2 (0.63) | ALDH1A1SRCMAPTLMNACA1 | |
| SCHEMBL3905759 | 0.76 | PEPD (0.55) | ALDH1A1GLAHSD17B10PEPDNPC1 | |
| SCHEMBL329313 | 0.76 | SRC (0.75) | SRCMEN1KMT2ACA1CA2 | |
| SCHEMBL5062623 | 0.76 | PEPD (0.80) | ALDH1A1GLAHSD17B10PEPDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | disclosed |
| EP-1113806-B1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA PTY LTD (AU) | 2007-09-05 | — | — | EP | disclosed |
| EP-0927217-B1 | ANGIOGENIC INHIBITORY COMPOUNDS | STARPHARMA PTY LTD (AU) | 2006-05-03 | — | — | EP | disclosed |
| EP-1113805-A4 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LTD (AU) | 2004-05-19 | — | — | EP | disclosed |
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | STARPHARMA LIMITED | 2003-07-10 | — | — | US | disclosed |
| EP-1113806-A4 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LTD (AU) | 2003-06-25 | — | — | EP | disclosed |
| EP-0927217-A4 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RES INST LTD (AU) | 2003-04-23 | — | — | EP | disclosed |
| US-6464971-B1 | ANIONIC-CONTAINING MOIETY IS A NEURAMINIC- OR SIALIC ACID-CONTAINING. MOIETY, IT IS MODIFIED IN THE 4-POSITION BY SUBSTITUTION WITH AN AMINO, AMIDO, CYANO, AZIDO OR GUANIDO GROUP, OR IS UNSATURATED. | STARPHARMA LIMITED (AU) | 2002-10-15 | — | — | US | disclosed |
| US-6426067-B1 | CARDIOVASCULAR DISORDERS; ANTITUMOR AGENTS | BIOMOLECULAR RESEARCH INSTITUTE, LTD. (AU) | 2002-07-30 | — | — | US | disclosed |
| EP-1113805-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | Starpharma Limited (AU) | 2001-07-11 | — | — | EP | disclosed |
| EP-1113806-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | Starpharma Limited (AU) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015240-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015239-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| EP-0927217-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998003573-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | FUT6, B3GNT2, SIGLEC7 | ALDH1A1 2800/4885GLA 828/4885HSD17B10 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.